Multisystem inflammatory syndrome in children — Initial therapy and outcomes

New England Journal of MedicineSon MBF, Murray N, Friedman K, et al. | June 18, 2021

Advertisement

Researchers aimed at assessing the real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C). Surveillance data on inpatients younger than 21 years of age who had MIS-C who were admitted to 1 of 58 US hospitals, were analyzed. They identified 518 patients with MIS-C (median age, 8.7 years) who underwent at least one immunomodulatory therapy; 75% of these had been previously healthy, and 9 died. Among these inpatients, a lower risk of new or persistent cardiovascular dysfunction was observed in correlation with receiving initial treatment with IVIG plus glucocorticoids vs IVIG alone.

Read the full article on New England Journal of Medicine

Advertisement